Multidrug-resistant (MDR) bacteria are a major threat to public health. Bacteriophage endolysins (lysins) are a promising alternative treatment to traditional antibiotics. However, the lysins currently under development are still underestimated. Herein, we cloned the lysin from the SAP-26 bacteriophage genome. The recombinant LysSAP26 protein inhibited the growth of carbapenem-resistant Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, oxacillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium with minimum inhibitory concentrations of 5~80 µg/mL. In animal experiments, mice infected with A. baumannii were protected by LysSAP26, with a 40% survival rate. Transmission electron microscopy analysis confirmed that LysSAP26 treatment resulted in the destruction of bacterial cell walls. LysSAP26 is a new endolysin that can be applied to treat MDR A. baumannii, E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli infections, targeting both Gram-positive and Gram-negative bacteria.

中文翻译：

---

LysSAP26，一种具有广谱抗菌活性的新型重组噬菌体内溶素

耐多药（MDR）细菌是对公共健康的主要威胁。噬菌体溶素（溶素）是传统抗生素的有前途的替代疗法。但是，目前正在开发的溶素仍被低估。本文中，我们从SAP-26噬菌体基因组中克隆了溶素。重组LysSAP26蛋白可抑制耐碳青霉烯的鲍曼不动杆菌，大肠杆菌，肺炎克雷伯菌和铜绿假单胞菌，耐奥沙西林的金黄色葡萄球菌以及耐万古霉素的粪肠球菌的生长，最低抑菌浓度为5〜80 µmL 。在动物实验中，感染鲍曼不动杆菌受到LysSAP26保护，存活率为40％。透射电镜分析证实LysSAP26处理导致细菌细胞壁的破坏。LysSAP26是一种新型内溶素，可用于治疗MDR鲍曼不动杆菌，粪肠球菌，金黄色葡萄球菌，肺炎克雷伯菌，铜绿假单胞菌和大肠杆菌感染，同时针对革兰氏阳性和革兰氏阴性细菌。